Kornimate/medical-research-clean huggingface dataset:
effect of low molecular heparin on pregnancy outcome with protein s deficiency

Conditions: Pregnancy Related; Protein S Deficiency

Summary: to evaluate whether low molecular heparin could improve pregnancy outcomes in pregnancies with protein s deficiency.

this is a parallel-group, multicenter, randomized controlled trial of 48 pregnancies with protein s deficiency in china. patients are randomized into three groups to receive enoxaparin combined with aspirin, aspirin alone and no intervention. the primary outcome measure is livebirth rate.

Eligibility criteria:
inclusion criteria: 1. plasma activity levels of ps when not pregnant are below the lower limits of the adult reference values (generally about 60-70% for ps) without the use of warfarin. or, free protein s antigen levels in the second and third trimesters are less than 30% and less than 24%, respectively 2. pregnant women who delivered from aug 1st, 2024 to oct 15th, 2027 3. one or more family members exhibiting the same symptoms as the patient 4. past history of early onset thrombosis (age 50 or below) 5. repeated recurrence of thrombosis 6. thromboses in unusual sites 7. new onset of thrombosis during current pregnancy or after delivery 8. patients with diagnosis confirmed by gene analysis inclusion criteria 1 and 2 must always be met regardless of items of 3-8. 9. written informed consent exclusion criteria: 1. thrombophilia other than protein s deficiency 2. antiphospholipid syndrome, systemic lupus erythematosus, platelet abnormalities, vascular disorders, blood flow obstruction, paroxysmal nocturnal hemoglobinuria, malignant tumor and other conditions that tend to cause thrombosis 3. allergy/hypersensitivity to enoxaparin or aspirin 4. heparin-associated thrombocytopenia or thrombocytopenia (platelet count\<75 × 10\^9/l) 5. organ lesions at risk for bleeding such as acute stomach/bowel ulcers, cerebral hemorrhage, cerebral aneurysm 6. uncontrolled hypertension or severe hypertension (systolic blood pressure \>200mmhg and/or diastolic blood pressure \>120mmhg) 7. severe hepatic failure (inr \>1.8) 8. serum creatinine greater than 80 umol/l (1.3mg/dl) and an abnormal 24 hour urine creatine clearance (\<30ml/min) 9. abnormal uterine cavity on hysterosalpingogram/hysteroscopy

Keywords: protein s deficiency pregnancy therapy
effect of ivabradine on patients with postural orthostatic tachycardia syndrome

Conditions: Postural Orthostatic Tachycardia Syndrome

Summary: postural orthostatic tachycardia syndrome (pots) occurs in approximately 500,000 americans, but predominates in women with a 5:1 ratio. patients with pots experience debilitating tachycardia upon postural changes such as standing that impairs their quality of life. tachycardia is clinically defined as a heart rate greater than 100 beats/min; and in pots patients, the prolonged heart rate increase is greater than 30 beats/min or increases to 120 beats/min within the first ten minutes of a diagnostic tilt table test without postural hypotension. there are currently no effective treatment methods for pots. however, several studies suggest ivabradine could be a main treatment option for pots because ivabradine specifically inhibits the f-channels (if) within the sinoatrial (sa) node, which slows the heart rate. currently in the us, ivabradine is mainly prescribed to treat chronic heart failure. it is well tolerated in patients, but it is not commonly prescribed for pots. it has been also used for treatment of inappropriate sinus tachycardia with good benefit. the hypothesis for this experiment is that ivabradine will reduce tachycardia and improve functional status in patients with pots.


Eligibility criteria:
inclusion criteria: * subjects aged 18-65. * subjects must have pots diagnosis (hyperadrenergic subtype with ne\> 600pg/ml)) * subjects with no structural heart disease * subject with no arrhythmias * subjects with norepinephrine levels greater than 600 pg/ml * subjects with normal cbc, metabolic, and thyroid levels exclusion criteria: * thyroid or adrenal disorders * drugs that interfere with ivabradine (example: cytochrome p450 drugs) * presentation of peripheral edema and discolored toes with peripheral autonomic neuropathy. symptoms include: legs (reduced hair growth, cramps), toes (blue color), legs/feet (wounds, ulcers that do not heal), and muscles (numbness, heaviness) * subjects who have had a history of systemic illnesses (acute or chronic infectious); autoimmune/ inflammatory disease, cancer, copd, anemia, diabetes, or psychiatric illness * subjects with resting heart rate\< 60beats/min, atrial fibrillation, advanced av blocks, sinus disease, and acute decompensated heart failure and severe hepatic impairment. * smokers or alcohol abuse * pregnant or breastfeeding mothers * woman of childbearing potential who are unwilling to use highly effective contraception during treatment and for an additional one month after discontinuing the study drug

Keywords: pots tachycardia ivabradine
assessment of the mental state of parents of premature children and impact on neurodevelopment of the child

Conditions: Parent-Child Relations

Summary: the objective of the study is to assess the psychic profile of parents of children born prematurely

prematurity affects aroound 1 in 10 children worlwide. many studies have shown the role of prematurity in the development of depression, anxiety, post-traumatic stress disorder, mother-to-child attachment disorders, but few studies have sought to assess the evolution of this profile over time as well as to assess all of the parents' psychic dimensions. the investigators currently have little knowledge of risk factors (psychological or psychiatric history, follow-up undertaken, treatments implemented, etc.) that may favor the occurrence of postpartum mental disorders (anxiety, depression, post-traumatic stress disorder ). the investigators will thus seek to identify them. prematurity can have a negative impact on the parents' psychic experience in the postpartum period. however, few studies have examined the evolution over time of the parental psychic profile and its possible repercussions on the child in terms of attachment and becoming neurodevelopmental. finally, the majority of studies dealing with these subjects concern only mothers.tthe investigators will endeavor here to also take into account the fathers.

Eligibility criteria:
inclusion criteria: parents whose child meets the following criteria: * singleton child * child aged up to 40 weeks of amenorrhea of age corrected at the time of inclusion * premature child as defined below: * born at a term less than or equal to 34 weeks of amenorrhea and or * weighing 1500g or less at birth * hospitalized in the neonatology department of the angers university hospital * child included in réseau grandir ensemble (rge) in pays de la loire * informed consent form signed by both parents for their participation and the collection of data from the rge for the child non-inclusion criteria: * parents not fluent in the french language, implying not being able to complete the various questionnaires * parents including the child : * is from a twin pregnancy or more * has polymalformative syndrome or chromosomal abnormalities exclusion criteria: - death of the child or one of the parents during follow-up

Keywords: prematurity psychic state
interest of colchicine in the treatment of patients with acute myocardial infarction and with inflammatory response

Conditions: Acute Myocardial Infarction

Summary: background: colchicine is an old well-known venerable drug routinely used in gout attacks for instance. more recnetly it is regularly use in the treatment of pericarditis. it couls exert antiiflammatory effects targeting the adverse inflammation occuring incase of acute myocardial infarction, which is involved in poor outcomes or longer stay at hospital. endpoints: * main endpoint: auc crp during the initial hospital stay * secondary endpoints: * clinical: oucomes * imaging: ett, mri * biological: various biomarkers method randomized, controled, open-labbelled, comparing two parallel arms: conventionnal optimal treatment versus conventionnal optimal treatment + colchicine


Eligibility criteria:
inclusion criteria: * acute myocardial inflarction (occlusion of coronary artery as assessed on the coronaro angiogram) * adult (18-90y) * men / women * aigned informed consent * health insurance exclusion criteria: * cardiogenic shock * digestive troubles * active bowels inflammatory disease (crhon, chronic, diarrhea...) * intolerance to the drug * renal insufficiency clearance \< 30ml/min * immunosuppression, aplasia * active infectious disease, active known neoplasia, chronic inflammatory disease * hypersensitivity, allergy to one of studies components * active liver disease * poor hemodynamic conditions * recent severe sepsis * chronic treatment with corticoids or no steroids antiinflammatory agents * no possibility for informed consent * protected by the law * poor abservance * history of toxicomania, suicice attempts * pregnacy, breeding, project of pregnancy

Keywords: acute myocardial infarction inflammation crp colchicine
examining the usage of dopamine blockers in ocd patients

Conditions: Obsessive Compulsive Disorder

Summary: we examine the usage of dopamine blockers in ocd patients. we want to examine their frequency of usage, compare the course of the disease between those who receive and those who do not receive dopamine blockers, and efficacy of the treatment. the study will be done in two stages: 1. collecting information the usage of dopamine blockers from 150 ocd patients' files. 2. interviewing 60-70 patients to see the difference those who receive and those who do not receive dopamine blockers in their current severity of disease.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age * dsm-iv diagnosis of ocd * ability to understand patient information sheet, and consent to participate exclusion criteria: * current or past psychotic or bipolar disorder
long-term follow-up study for non-hodgkin's lymphoma patients who received study treatment (plerixafor or placebo) in the amd3100-3101 study (nct00103610).

Conditions: Non-Hodgkin's Lymphoma; Autologous Transplantation

Summary: this is a long-term observational study of patients that were treated with at least 1 dose of study treatment (plerixafor or placebo) in the amd3100-3101 protocol (nct00103610).

this is a long-term observational study of patients who received at least one dose of study treatment (plerixafor or placebo) in a multicenter, randomized, double blind, placebo-controlled investigational study to evaluate granulocyte colony stimulating factor (g-csf) plus amd3100 versus g-csf plus placebo to mobilize and transplant non-hodgkin's lymphoma (nhl) patients (protocol amd3100-3101 \[nct00103610\]). the objective of this study is to assess progression-free survival and overall survival of patients treated with at least 1 dose of study treatment (placebo or plerixafor) for a period of 5 years following the first dose of study treatment (placebo or plerixafor) in protocol amd3100-3101 (nct00103610).

Eligibility criteria:
inclusion criteria: * all patients who received a dose of study treatment (plerixafor or placebo)in protocol amd3100-3101 (nct00103610) exclusion criteria: * no exclusion criteria
a study to characterize the pharmacokinetics/pharmacodynamics and effect of food of da-1229 in healthy male subjects

Conditions: Diabetes Mellitis Type 2

Summary: this is a dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation study. the study is designed to describe the relationship between multiple doses and pharmacokinetic/pharmacodynamic parameters of da-1229 as well as safety profile.


Eligibility criteria:
inclusion criteria: * 20-45 years healthy male subjects * body weight :50-90kg, bmi between 18.5-25 * blood glucose level of 70-110mg/dl on the fpg test exclusion criteria: * have a family history of diabetes * serum ast(sgot), alt(sgpt)\>1.25 times upper limit of normal * creatinine clearance rate\<80ml/min * show sbp =\ =150mmhg, or dbp=\ =95mmhg, or tachycardia (pr\>=100times/min) * have a history of drug abuse or show positive for drug abuse or cotinine at urine screening * smokers * can not digest high-fat or high-calorie food(applicable only for the 10mg dose group subjects
alcohol and the social brain: an alcohol-administration hyperscanning study

Conditions: Alcohol Drinking; Alcohol Use Disorder; Alcohol Intoxication; Alcohol; Harmful Use; Alcoholism; Binge Drinking

Summary: in this study, the investigators aim to capture inter- and intra-brain mechanisms underlying alcohol reward in novel social context.

objective: alcohol's ability to boost mood in the face of stress is perhaps its most notoriously addictive property, long held by researchers to be of critical importance for understanding alcohol use disorder (aud) etiology. yet, while most real-world alcohol consumption occurs in social settings, in the context of laboratory studies, participants have almost always consumed alcohol alone. the discrepancy between real-world and laboratory contexts emerges as particularly stark in the neuroimaging literature, where no alcohol-administration study to date has incorporated in-vivo social context. in this first alcohol-administration study to leverage eeg hyperscanning methods, the investigators aim to capture inter- and intra-brain mechanisms underlying alcohol reward in novel social context. specifically, this study aims to characterize the mechanisms driving social reward from alcohol in the context of stress and elucidate the role of social processes and novel social context in driving problem drinking. study population: participants will consist of 240 regular drinkers, aged 21-30, with no reported history of severe alcohol use disorder. design: in the laboratory arm of the study, individuals will be randomly assigned to consume either a moderate dose of alcohol or a control beverage in stranger dyads. participants will engage in both structured and unstructured tasks aimed at assessing social engagement and threat sensitivity. eeg and erp data will be collected from both participants simultaneously. in the ambulatory study arm, participants will wear transdermal sensors to assess bac and will further provide information about their mood and their social contexts in response to random prompts. outcome measures: primary outcome measures include eeg measures of inter-brain entrainment as well as erp metrics derived from task contexts (both players and observers). additional outcomes include measures of positive mood, negative mood, and social bonding. finally, drinking behaviors will be assessed via transdermal ambulatory alcohol sensors and longitudinal self-reports of drinking.

Eligibility criteria:
inclusion criteria: * between the ages of 21 and 30 * regularly consumes alcohol exclusion criteria: * history of adverse reaction to the amount of beverage employed in the study * have a history of major problems associated with alcohol * take medications that could adversely interact with alcohol * have medical conditions that contraindicate alcohol administration * individuals with a history of skull fractures or who indicate discomfort with eeg procedures used * female participant is pregnant or trying to become pregnant
omentectomy for metabolic syndrome in gastric cancer patients

Conditions: Metabolic Syndrome; Gastric Cancer

Summary: many features of the metabolic syndrome are associated with insulin resistance. and, metabolic syndrome and insulin resistance are related to visceral obesity. therefore, the investigators hypothesized that visceral fat removal (omentectomy) can make favorable results for the insulin resistance and metabolic syndrome. as the omentectomy is optional procedure during a surgery for early gastric cancer, the investigators will divide patients randomly into two groups, total omentectomy group and omentum preserving group.

the investigators will compare the change of insulin resistance (homa-ir) and improvement of metabolic syndrome between total omentectomy and omentum preserving group.

Eligibility criteria:
inclusion criteria: * histologically confirmed adenocarcinoma in stomach * aged≥20 years and ≤80 years * scheduled as laparoscopic distal gastrectomy (ct1n0m0 or ct2n0m0) * metabolic syndrome (ncep:atp iii (national cholesterol education program and adult treatment panel iii) -harmonizing definition criteria * ecog 0 (eastern cooperative oncology group) * asa score class i-iii (american society of anesthesiologists) * patient has given their written informed consent to participate in the study exclusion criteria: * simultaneously combined resection of other organ * active other malignancy * expected to severe intra-abdominal adhesion due to previous abdominal operation history * uncontrolled co-morbidity * vulnerable patients

Keywords: metabolic syndrome gastric cancer omentectomy
correlation between end-tidal co2 and degree of compression of heart during cpr measured by ultrasound

Conditions: Cardiopulmonary Resuscitation; Echocardiography

Summary: individual optimization of cardiopulmonary resuscitation (cpr) in real time may increase the success rate of the procedure. end-tidal co2 (etco2) levels reflect cardiac output induced by cpr. other potential marker of haemodynamic efficacy of cpr is direct measurement of the extent of induced compression of left ventricle (lv), right ventricle (rv) and inferior caval vein (ivc) by ultrasound. we plane to evaluate whether these ultrasound parameters correlate with etco2 levels during cpr for out-of-hospital cardiac arrest (ohca) of non-traumatic origin.

pre-hospital observational study will be realized in the setting of physician-based emergency medical system in the czech republic. 20 patients resuscitated for ohca of nontraumatic origin are planned to be included to the study. transthoracic echocardiography will be performed from subcostal view during ongoing chest compressions in all of them and in the time of this investigation etco2 level will be recorded. this will be repeated three times during cpr in each patient if possible. later on, maximal and minimal diameter of lv, rv and ivc will be obtained from the recorded loops and compression index (%) of lv (lvci), rv (rvci) and ivc (ivcci) will be calculated as (maximal-minimal/maximal cavital diameter)x100. correlations between etco2 and lvci, rvci and ivci and cimax will be expressed as spearman's correlation coefficient. the results of the study will answer the question whether echocardiographic evaluation of compression of heart cavities during cpr reflect haemodynamic efficacy of cpr. if so, this study will be followed by an interventional clinical trial evaluating the effect of compression depth changes as a response to measured compression of the heart.

Eligibility criteria:
inclusion criteria: * adult patient resuscitated for out-of-hospital cardiac arrest of non-traumatic origin. exclusion criteria: * technical unavailability of intra-arrest ultrasonography and capnography.
the north-west inter regional female cohort for patients with endometriosis

Conditions: Endometriosis

Summary: all women managed for endometriosis are included and followed up through the cirendo database. information is obtained from surgical and histological records and from self-questionnaires completed before surgery. standardized gastrointestinal questionnaires (kess, giqli, wexner, fiql and bristol) are routinely used to assess bowel function. data recording, patient contact and follow-up are carried out by a clinical research technician. postoperative follow-up is based on data from the afore-mentioned questionnaires completed at 1, 3, 5 and 7 years.

all women managed for endometriosis are included and followed up through the cirendo database (the north-west inter regional female cohort for patients with endometriosis), a prospective cohort financed by the g4 group (the university hospitals of rouen, lille, amiens and caen), and coordinated by the principal investigator (h.r.). information is obtained from surgical and histological records and from self-questionnaires completed before surgery. standardized gastrointestinal questionnaires (kess, giqli, wexner, fiql and bristol) are routinely used to assess bowel function. data recording, patient contact and follow-up are carried out by a clinical research technician. women are included in the cirendo database only when endometriosis is confirmed by both surgical exploration and biopsy. postoperative follow-up is based on data from the afore-mentioned questionnaires completed at 1, 3, 5 and 7 years. prospective data recording and analysis were approved by the french authorities cnil (commission nationale de l'informatique et des libertés) and cctirs (comité consultatif pour le traitement de l'information en matière de recherche dans le domaine de la santé).

Eligibility criteria:
inclusion criteria: * endometriosis revealed on histological specimens exclusion criteria: * none

Keywords: deep endometriosis; colorectal endometriosis surgery medical treatment fertility
comparison of citrate and heparin anticoagulation during hemodialysis with mco pes-pvp (theranova) membrane

Conditions: End Stage Renal Disease; Haemodialysis; Anticoagulation

Summary: the purpose of the study is to compare the efficiency and biocompatibility of citrate and heparin anticoagulation during hemodialysis with medium cut-off polyarylethersulphone-polyvinylpirrolidone membrane (theranova®).

the purpose of the study is to compare the efficiency and biocompatibility of citrate and heparin anticoagulation during hemodialysis (hd) with pes-pvp membrane. the research will be performed as a prospective clinical trial and will include 35 patients. every patient will have 2 hd procedures with pes-pvp membrane in a randomized order: 1 with unfractionated heparin (ufh) and 1 with 8% trisodium citrate. we will compare the efficiency of both types of anticoagulation by measuring overall and instantaneous clearances of small, middle and protein-bound molecules (urea, creatinine, phosphate, β2-microglobulin, p-cresol). biocompatibility will be evaluated by measuring activation of: complement (serum concentration of c3a and c5a), leukocytes (serum concentration of myeloperoxidase) and thrombocytes (serum concentration of pf4). we will also monitor complete blood count for occurrence of leukopenia and thrombocytopenia. after the hd electron microscopy of the membrane will be done in the proportion of included patients to evaluate adsorption of cells and formation of blood clots on the membrane.

Eligibility criteria:
inclusion criteria: * patient on chronic hemodialysis * age 18 years old or more * being able to give an informed consent to participate in the survey exclusion criteria: * on therapeutic anticoagulation * citrate or heparin contraindicated * citrate or heparin intolerance * acute renal failure